Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Treg cell Notch receptors drive SARS-CoV-2-induced MIS-C

In a recent study under consideration at Nature Portfolio Journal and posted to the Research Square* preprint server, researchers demonstrated the evolution of multi-system inflammatory syndrome in children (MIS-C) following acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

12 Apr 2022

Decoy nanoparticles could provide a quick, effective treatment for COVID-19

They might look like cells and act like cells. But a new potential COVID-19 treatment is actually a cleverly disguised trickster, which attracts viruses and binds them, rendering them inactive.

12 Apr 2022

Alternative anti-HIV strategy generates promising results in a phase I clinical trial

vaccines against the virus, but unfortunately, HIV has numerous defense mechanisms that prevent a person's immune system from mounting an effective response following HIV vaccination.

11 Apr 2022

New research on SARS-CoV-2 Omicron variant mutations and sotrovimab therapy

A recent study posted to the medRxiv* preprint server assessed the impact of sotrovimab treatment on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant-infected immunocompromised (IC) patients.

11 Apr 2022

Immunocompromised hosts with Delta/Omicron co-infections

A recent study posted to the medRxiv* preprint server examined clinical cases of co-infections of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta/Omicron variants and Omicron BA.1/ BA.2 sublineages in immunocompromised (IC) patients.

10 Apr 2022

Improved seroprevalence and antibody response after third COVID-19 vaccination

Researchers evaluated the immunogenicity of a third COVID-19 vaccination in antibody deficient subjects.

8 Apr 2022

Sotrovimab found to prevent hospitalization and mortality in COVID-19 outpatients

Researchers tested the efficacy of sotrovimab in non-hospitalized patients with SARS-CoV-2 infection.

7 Apr 2022

Developing and manufacturing custom recombinant antibodies for R&D

In this interview, Dr. Linlin Zhang, technical specialist for Sino Biological Europe, discusses how Sino is expanding its product offerings into the European market and outlines its process for developing and manufacturing custom recombinant antibodies for their clients.

From Sino Biological Inc. 6 Apr 2022

Study says duplilumab reduces mortality from COVID-19

A recent report posted to the medRxiv* preprint server assessed the efficacy of dupilumab in blocking the IL-13 signaling pathway and its efficacy in reducing the COVID-19 associated mortality.

5 Apr 2022

Recombinant fragment of the lectin-binding region of Gal-3BP stimulates the expression of IL-6 in SARS-CoV-2 sensitive cells

A recent study investigated the impact of a recombinant fragment of cellular glycoprotein Gal-3BP on IL-6 expression in acute COVID-19.

5 Apr 2022

NIH program provides a real-time risk assessment of variants of SARS-CoV-2

Faculty from the Departments of Microbiology, Medicine Genetics and Genomic Sciences, and Pathology and Molecular Cell-Based Medicine at the Icahn School of Medicine at Mount Sinai play key roles in a National Institutes of Health (NIH) program set up to provide a real-time risk assessment of variants of SARS-CoV-2, the virus that causes COVID-19. The program, called SARS-CoV-2 Assessment of Viral Evolution (SAVE) and described in a paper published March 31 in Nature, assesses how the variants might affect transmission, virulence, and resistance to both disease-induced (convalescent) and vaccine-induced immunity.

31 Mar 2022

Therapeutic antibodies against filoviruses including Ebola and Marburg

Researchers discuss the development and structural characterization of therapeutic monoclonal antibodies targeting the surface glycoprotein of filoviruses.

31 Mar 2022

Research provides a roadmap for new therapies to treat chorioamnionitis

One of the serious complications that can occur during late pregnancy happens when the amniotic sac (also called the bag of waters) breaks too early, which can allow bacterial infections to cause dangerous tissue inflammation around the placenta.

30 Mar 2022

ACE2 decoy receptor with robust neutralization against Omicron subvariants shows therapeutic potential

Researchers demonstrated the inhalation of an ACE2 decoy receptor, sACE22.v2.4-IgG1, increases survival and ameliorates lung injury in K18-hACE2 transgenic mice.

30 Mar 2022

Evaluating serological responses to repeated COVID-19 vaccination in kidney transplant recipients

Researchers analyzed whether repeated vaccinations against COVID-19 increase serological response in non-responding kidney transplant recipients.

29 Mar 2022

Northwestern scientists continue to advance the understanding of COVID-19

As the COVID-19 pandemic enters its third year, Northwestern Medicine scientists continue to help advance the understanding of the disease and its impact, from investigating antibody protection against COVID-19 reinfection to elevating women in academic research and highlighting racial and ethnic disparities in COVID-19 hospital mortality in Illinois.

28 Mar 2022